CRE for Interstitial Lung Disease - towards Individualised Care

  • Corte, Tamera Jo (Primary Chief Investigator (PCI))
  • Holland, Anne (Chief Investigator (CI))
  • Chambers, Daniel Charles (Chief Investigator (CI))
  • Hansbro, Philip Michael (Chief Investigator (CI))
  • Dickinson, Joanne L (Chief Investigator (CI))
  • Palmer, Andrew John (Chief Investigator (CI))
  • Moodley, Yuben P. (Chief Investigator (CI))
  • Powell, Joseph E (Chief Investigator (CI))
  • Knibbs, Luke D. (Chief Investigator (CI))
  • Smallwood, Natasha (Chief Investigator (CI))
  • Brooke, Mark (Associate Investigator (AI))
  • Glaspole, Ian (Associate Investigator (AI))
  • Goh, Nicole Soo Leng (Associate Investigator (AI))
  • Westall, Glen (Associate Investigator (AI))
  • Reynolds, Paul N. (Associate Investigator (AI))
  • Hancock, Kerry (Associate Investigator (AI))
  • Troy, Lauren K. (Associate Investigator (AI))
  • Mackintosh, John A. (Associate Investigator (AI))
  • Price, David P.T. (Associate Investigator (AI))
  • Dowling, Jason (Associate Investigator (AI))

Project: Research

Project Details

Project Description

Interstitial lung disease (ILD) encompasses a group of lung disorders characterised by fibrosis of the lung tissue. With our successful prior CRE (CRE-PF, 2017), focused on one specific ILD, idiopathic pulmonary fibrosis (IPF), we are at the forefront of international developments prompting a new and individualised approach. Recent advances show there are common underlying genetic and biological pathways, and new anti-fibrotic medications are effective across the whole ILD spectrum, indicating that it is now appropriate to broaden our focus to all patients with ILD. In this CRE-ILD, we bring together a new multidisciplinary, diverse team from across Australia, to address patientidentified research priorities.
The overarching goals of the CRE-ILD are to transform and extend the lives of people with ILD, through the development of more effective, personalized approaches to diagnosis and management. Specifically, we will:
1. Improve understanding of genetic and environmental causes of ILD and enable prevention through earlier, more
accurate diagnosis.
2. Identify patients with a progressive phenotype, enabling the development of therapeutic targets to prevent
disease progression and enhance survival.
3. Develop new treatments to improve symptoms, quality of life for ILD patients.
4: Ensure rapid and direct translation of our research outcomes into both policy and practice, ensuring best practice
care for ILD patients across all areas of regional and urban Australia.
5: Build on our highly successful ILD national training scheme,
6. Further our existing extensive national and international collaborations.
In Australia, we are uniquely positioned to achieve these goals, due to our highly successful CRE-PF and its
exceptional national infrastructure, as we broaden our reach from IPF the entire spectrum of ILD with a
transformative personalised approach.
Short titleCRE for ILD
StatusActive
Effective start/end date1/11/2231/10/27

Funding

  • National Health and Medical Research Council (NHMRC) (Australia): A$2,500,000.00

Keywords

  • respiratory diseases
  • pulmonary fibrosis